SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization (WHO) Europe. Strategic objectives for WHO health in prisons project. 2007. Available at: http://euro.who.int/prisons/20060508_1 (accessed 8 December 2009).
  • 2
    World Health Organization (WHO). Hepatitis B. Factsheet no. 204. 2009. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ (accessed 8th December 2009).
  • 3
    Hutchinson S., Wadd S., Taylor A. et al. Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. Vaccine 2004; 23: 2104.
  • 4
    Jurgens R., Ball A., Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 2009; 9: 5766.
  • 5
    Gilbert R. L., Costella A., Piper M., Gill O. N. Increasing hepatitis B vaccine coverage in prisons in England and Wales. Commun Dis Public Health 2004; 7: 30611.
  • 6
    Mangtani P., Hall A. J., Normand C. E. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health 1995; 49: 23844.
  • 7
    Farrell M., Battersby M., Strang J. Screening for hepatitis B and vaccination of injecting drug users in NHS drug treatment services. Br J Addict 1990; 1990: 16579.
  • 8
    Winstock A., Sheridan J., Lovell S., Farrell M., Strang J. National survey of hepatitis testing and vaccination services provided by drug services in England and Wales. Eur J Clin Microbiol Infect Dis 2000; 19: 8238.
  • 9
    Bayas J., Bruguera M., Martin V. et al. Hepatitis B vaccination in prisons: the Catalonian experience. Vaccine 1993; 11: 14414.
  • 10
    Rich J. D., Ching C. G., Lally M. A., Gaitanis M. M., Schwartzapfel B., Charuvastra A. et al. A review of the case for hepatitis B vaccination of high-risk adults. Am J Med 2003; 114: 3168.
  • 11
    Christensen P. B., Fisker N., Krarup H. B. et al. Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. Vaccine 2004; 22: 3897901.
  • 12
    Hope V. D., Ncube F., Hickman M., Judd A., Parry V. Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements? J Viral Hepatol 2007; 14: 65360.
  • 13
    Gilbert R., Costella A., Piper M. et al. Increasing hepatitis B vaccine coverage in prisons in England and Wales. Commun Dis Public Health 2004; 7: 30611.
  • 14
    Sharfstein J., Wise P. H. Inadequate hepatitis B vaccination of adolescents and adults at an urban community health center. J Natl Med Assoc 1997; 1997: 8692.
  • 15
    Rich J. D., Ching C. D., Lally M. A. et al. A review of the case for hepatitis B vaccination of high-risk adults. Am J Med 2003; 114: 3168.
  • 16
    Pisu M., Meltzer M. I., Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 2002; 21: 31221.
  • 17
    Sutton A. J., Gay N. J., Edmunds W. J. et al. Modelling the hepatitis B vaccination programme in prisons. Epidemiol Infect 2006; 134: 231.
  • 18
    Health Protection Agency. Prison hepatitis B vaccination programme monitoring, 2003–2006. Monthly reports. 2009. Available at: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1237889544922 (accessed April 2009).